(E)-N'-(3-(2-bromophenyl)acryloyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carbohydrazide | 1615678-01-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-N'-(3-(2-bromophenyl)acryloyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carbohydrazide
• 英文别名: N'-[(E)-3-(2-bromophenyl)prop-2-enoyl]-2,3-dihydro-1,4-benzodioxine-6-carbohydrazide
• CAS: 1615678-01-7
• 化学式: C₁₈H₁₅BrN₂O₄
• 分子量: 403.232
• InChiKey: WFRIZSONSNLVDC-SOFGYWHQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  76.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  苯并二氧六环-6-甲酸甲酯 在 hydrazine hydrate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 128.0h， 生成 (E)-N'-(3-(2-bromophenyl)acryloyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carbohydrazide
  参考文献：
  名称：

  Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors

  摘要：

  A novel class of aromatic diacylhydrazine derivatives was designed as PLK1 inhibitors. All the 19 new synthesized compounds were assayed for antitumor activity against the respective cervical cancer cells. In which, nine compounds with better antitumor activities were further tested for their PLK1 inhibitory activity. Last, we have successfully found that compound 7k showed both the promising antitumor activity with IC50 of 0.17 mu M against the cervical cancer cells, and also processed the most potent PLK1 inhibitory activity with IC50 of 0.03 mu M. In addition, docking simulation also carried out in this study to give a potent prediction binding mode between the small molecule and PKL1 (PDB code: 1umw) protein. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.05.026

文献信息

• Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors
  作者：Juan Sun、Peng-Cheng Lv、Feng-Jiao Guo、Xin-Yi Wang、Xiao- Han、Yang Zhang、Gui-Hua Sheng、Shao-Song Qian、Hai-Liang Zhu

  DOI：10.1016/j.ejmech.2014.05.026

  日期：2014.6

  A novel class of aromatic diacylhydrazine derivatives was designed as PLK1 inhibitors. All the 19 new synthesized compounds were assayed for antitumor activity against the respective cervical cancer cells. In which, nine compounds with better antitumor activities were further tested for their PLK1 inhibitory activity. Last, we have successfully found that compound 7k showed both the promising antitumor activity with IC50 of 0.17 mu M against the cervical cancer cells, and also processed the most potent PLK1 inhibitory activity with IC50 of 0.03 mu M. In addition, docking simulation also carried out in this study to give a potent prediction binding mode between the small molecule and PKL1 (PDB code: 1umw) protein. (C) 2014 Elsevier Masson SAS. All rights reserved.